Medy-Tox (086900) Fundamentals 2026 — P/E 21.4x, Revenue Analysis | SniperIQ
Medy-Tox (086900) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩445.1B, trading at ₩68300.00 on the KOE. This SniperIQ fundamentals page covers Medy-Tox's valuation (P/E 21.4x, P/B 1.3x), profitability (net margin 8.4%), revenue (₩247.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Medy-Tox's market cap?
Medy-Tox (086900) has a market capitalization of approximately ₩445.1B, trading at ₩68300.00 on the KOE. Market cap moves with the live share price.
What is Medy-Tox's P/E ratio?
Medy-Tox's trailing twelve-month P/E ratio is 21.4x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Medy-Tox?
Medy-Tox runs a net profit margin of 8.4%, a gross margin of 58.2%, and an operating margin of 7.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Medy-Tox generate?
Medy-Tox reported revenue of ₩247.3B for fiscal year 2025, with net income of ₩16.6B and earnings per share (EPS) of 2371. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Medy-Tox pay a dividend?
Medy-Tox offers a trailing dividend yield of about 1.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Medy-Tox financially healthy?
Medy-Tox carries a debt-to-equity ratio of 0.33x and a current ratio of 1.01x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Medy-Tox a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Medy-Tox (086900) the key facts are: market cap ₩445.1B, P/E 21.4x, revenue ₩247.3B, 52-week range 67700-157600. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Medy-Tox's full fundamentals live
Get Medy-Tox's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.